• Skip to main content

Plain Language Summaries

Standalone, citable summaries published in the Future Science Group journals written to be understood by a lay audience

  • How To Publish
  • How to Write Plain Language Summaries
  • Frequently Asked Questions
  • Publications
    • Animated Videos
    • Bladder, Kidney and Genitals
    • Brain and Nerves
    • Cancer
    • Diabetes and Metabolic Hormones
    • Eyes and Vision
    • Heart and Circulation
    • Infections
    • Inflammatory and Immune-related disorders
    • Mental Health
    • Muscle and Bone
    • Rare Diseases
    • Skin
    • Vaccines
  • Advisory Panel
  • Supporters
  • Blog
  • About Us
  • Contact Us

May 20 2022

Plain language summary of the HERO study comparing relugolix with leuprolide for men with advanced prostate cancer

The HERO study compared how well relugolix and leuprolide worked in lowering blood testosterone to sustained castration levels in men with advanced prostate cancer. This is plain language summary provides an overview of this study.

Read the full article here.

Click here to read the original article on which this summary is based.

  • Share on Twitter Share on Twitter
  • Share on Facebook Share on Facebook
  • Share on LinkedIn Share on LinkedIn

Written by Joanne Walker · Categorized: Bladder, Kidney and Genitals, Cancer · Tagged: advanced prostate cancer, androgen-deprivation therapy, clinical trial, GnRH agonist, GnRH antagonist, leuprolide

Copyright © 2023 · Plain Language Summaries · Terms and Conditions · Privacy Policy ·